Literature DB >> 21537334

DNMT3A mutations in myeloproliferative neoplasms.

F Stegelmann, L Bullinger, R F Schlenk, P Paschka, M Griesshammer, C Blersch, S Kuhn, S Schauer, H Döhner, K Döhner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21537334     DOI： 10.1038/leu.2011.77

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  68 in total

Review 1.  Disordered epigenetic regulation in the pathophysiology of myeloproliferative neoplasms.

Authors:  Su-Jiang Zhang; Omar Abdel-Wahab
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

2.  Recurring mutations in myeloproliferative neoplasms alter epigenetic regulation of gene expression.

Authors:  Gary W Reuther
Journal:  Am J Cancer Res       Date:  2011-05-29       Impact factor: 6.166

3.  Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia.

Authors:  Isabella Fried; Claudia Bodner; Monika M Pichler; Karin Lind; Christine Beham-Schmid; Franz Quehenberger; Wolfgang R Sperr; Werner Linkesch; Heinz Sill; Albert Wölfler
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 4.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

5.  Inherited predisposition to myeloproliferative neoplasms.

Authors:  Amy V Jones; Nicholas C P Cross
Journal:  Ther Adv Hematol       Date:  2013-08

6.  Uses and abuses of JAK2 and MPL mutation tests in myeloproliferative neoplasms a paper from the 2010 William Beaumont hospital symposium on molecular pathology.

Authors:  Ayalew Tefferi; Pierre Noel; Curtis A Hanson
Journal:  J Mol Diagn       Date:  2011-06-30       Impact factor: 5.568

7.  Tetraspanin CD9 participates in dysmegakaryopoiesis and stromal interactions in primary myelofibrosis.

Authors:  Christophe Desterke; Christophe Martinaud; Bernadette Guerton; Lisa Pieri; Costanza Bogani; Denis Clay; Frederic Torossian; Jean-Jacques Lataillade; Hans C Hasselbach; Heinz Gisslinger; Jean-Loup Demory; Brigitte Dupriez; Claude Boucheix; Eric Rubinstein; Sophie Amsellem; Alessandro M Vannucchi; Marie-Caroline Le Bousse-Kerdilès
Journal:  Haematologica       Date:  2015-04-03       Impact factor: 9.941

Review 8.  Prognosis of Primary Myelofibrosis in the Genomic Era.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2016-08

9.  Mutations in the DNMT3A DNA methyltransferase in acute myeloid leukemia patients cause both loss and gain of function and differential regulation by protein partners.

Authors:  Jonathan E Sandoval; Yung-Hsin Huang; Abigail Muise; Margaret A Goodell; Norbert O Reich
Journal:  J Biol Chem       Date:  2019-01-31       Impact factor: 5.157

10.  Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients.

Authors:  Eun-Hyung Yoo; Kyung-Jin Park; Hong-Hee Won; Jun-Hee Park; Jong-Ho Park; Seung-Tae Lee; Hee-Jin Kim; Soo-Mee Bang; Hyun-Sook Chi; Chul Won Jung; Sun-Hee Kim; Hongseok Yun; Choong-Hyun Sun; Inho Park; Seungmook Lee; Clarence Lee; Barry Merriman; Raymond Luo; Eileen Hwee Hong Tan; Keun-Joon Park; Na-Kyung Yoo; Jason J Kang; Jong-Won Kim
Journal:  J Clin Lab Anal       Date:  2016-05-02       Impact factor: 2.352
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.